Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD - Nature Biotechnology

  • 📰 NatureBiotech
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 63%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

This work was funded by the Commonwealth Fund, as well as from a grant to W.B.F. A.S.K.’s work was also supported by Arnold Ventures. R.B.’s work is funded by an O’Brien Institute of Public Health catalyst grant for equitable pharmaceutical innovation and access to medicines. The funders had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; review or approval of the manuscript; or decision to submit the manuscript for publication.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

Brand name inhalers are very good at blocking competition, better even than nebulizers, study finds NBTintheNews via endpts

BrighamWomens harvardmed UCalgaryMed PORTAL_Research wbfeldman ReedBeall

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 231. in KR

대한민국 최근 뉴스, 대한민국 헤드 라인